The U.S. Food and Drug Administration (FDA) on Wednesday granted
breakthrough therapy designation to drug maker, AstraZeneca’s biggest
new drug hope Durvalumab for the treatment in bladder cancer.
The experimental medicine is a “PD-L1’’ therapy that fights cancer by boosting the immune system.
The breakthrough therapy designation expedites the development and
review of medicines intended to treat serious or life-threatening
diseases.
The drug, Durvalumab, is also being developed as a treatment for
lung, head and neck, gastric, pancreatic, liver and blood cancers.
No comments:
Post a Comment